- Home
- DeteCas™
- Services
- Applications
- About
- Careers
- Contact
Gastric cancer is one of the common malignant tumors derived from gastric mucosa epithelial cells, and its morbidity and mortality ranks second among malignant tumors in the world.
| Common Type | Special Type |
|---|---|
|
|
|
|
|
|
|
|
|
The 5-year survival rate of early gastric cancer after treatment can reach more than 90%. Therefore, early detection and early treatment are essential to reduce the mortality rate of gastric cancer.
Endoscopy is the most effective means of diagnosing gastric cancer. Not only can the location and shape of the lesion be visually seen, but also the lesion tissue can be directly taken for cytological and pathological examinations to obtain evidence of pathological diagnosis, and various treatments can be performed through gastroscope. In addition, endoscopy is also an important means and tool for gastric cancer screening.
Standard pathological diagnosis of gastric cancer includes gross anatomical findings (tumor size, growth pattern), depth of invasion, histological type, degree of differentiation, lymph node involvement, and immunohistochemical examination.
Laparoscopy can make up for the deficiencies of some laboratory tests and imaging examinations, re-identify clinical M (distant metastasis) and T (primary tumor) staging, avoid unnecessary laparotomy, and provide further diagnosis and treatment. reliable basis. In addition, while completing laparoscopic diagnosis, surgical treatment can also be completed within a certain range.
The recurrence of intraperitoneal metastasis is the main cause of death in patients with gastric cancer, and the reason is the presence of free cancer cells in the abdominal cavity. Peritoneal lavage cytology is the "gold standard" for detecting free peritoneal cancer cells, and has become an important means of predicting "potential peritoneal metastasis".
Tumor biomarkers of gastric cancer can be detected by line immunoassay (LIA), enzyme-linked immunosorbent assay (ELISA), and CRISPR molecular diagnostic techniques.
Utilizing the DeteCasTM platform based on the CRISPR-Cas system, CD BioSciences can provide various services in stomach cancer diagnosis, such as nucleic acids detection service, protein biomarker detection service and small molecule detection service. If you are interested in these services, please contact us.
References
